What one share of Neonc Technologies Holdings holds
Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain.
Neonc Technologies Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$2.14 |
| Cash and investments | $0.08 |
| Debt | $0.01 |
| Book value | −$0.71 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | $0.00 | −$0.69 | — | — | — | −$0.30 |
| 2025 | $0.00 | −$3.20 | $0.03 | −$1.08 | — | −$0.80 |
Common questions about Neonc Technologies Holdings
How much does one share of Neonc Technologies Holdings earn?
Over the last 12 months, Neonc Technologies Holdings lost $2.14 for each share.
Does Neonc Technologies Holdings pay a dividend?
Neonc Technologies Holdings didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Neonc Technologies Holdings’s book value per share?
Neonc Technologies Holdings’s book value is negative (−$0.71 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Neonc Technologies Holdings have?
Each share of Neonc Technologies Holdings has $0.08 of cash and investments and $0.01 of debt, as of June 30, 2026.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.